Thermo Fisher forges $1.7 billion deal to buy a contract player in the booming gene therapy field
Thermo Fisher is snapping up one of the newborn contract players in the burgeoning gene therapy field.
The company announced late Sunday night that they are buying Brammer Bio — which handles contract viral vector manufacturing for cell and gene therapy developers — for $1.7 billion.
Gene therapies may be just at the beginning stages of commercialization, but a host of new programs has begun to attract the majors in a slate of buyout deals, topped by Roche’s $4.3 billion deal to acquire Spark. Behind that you’ll find a group of outsourcing companies offering the tech and manufacturing know-how to do much of the work under contract, which is where Thermo Fisher is positioning itself now.
Basic subscription required
Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.